National Institute of Allergy and Infectious Diseases (NIAID)

🚀 Dreaming of a career where you can make a difference? Discover the endless possibilities at NIAID with our #recruitment video. Whether you’re passionate about science, administration, or innovation, there is a place for you. Learn more from some of the dedicated public servants who make NIAID a great place to work: https://lnkd.in/e-sD2kX5 #PSRW #NIAIDCareers

Looking for ways to counter Epstein-Barr virus (EBV), NIAID researchers are examining how the virus recognizes and interacts with cells at the molecular level. New research reveals the high-resolution crystal structure of a protein on the surface of EBV in complex with the receptor it binds to on the surface of human immune cells, called B cells. The researchers also discovered antibodies that potently neutralize EBV and found that they recognize the viral surface protein using interactions similar to those between EBV and its receptor on host cells. This research identifies a vulnerable site on EBV that could lead to the design of much-needed interventions against the virus, which causes mononucleosis (mono for short) and some types of cancer and autoimmune diseases. Learn more at https://go.nih.gov/UjqeA4K #EpsteinBarrVirus #NIAID #NIAIDVRC #cancer #autoimmunity

The medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very small amounts of common food allergens, a #NIAID-funded clinical trial has found. Researchers attributed this difference primarily to the high rate of allergic reactions and other intolerable side effects among the study participants who received OIT, leading a quarter of them to discontinue treatment. Omalizumab and OIT were equally effective among participants who completed treatment. Learn more: https://go.nih.gov/dYNo5T5 #NIH #research #ResearchAdvance #FoodAllergy #FoodAllergies #allergic #allergy #immunotherapy #OIT #FoodAllergyTreatment #omalizumab Johns Hopkins Children's Center Stanford University School of Medicine Genentech

At #NIAID, we offer a range of resources to support your #research efforts. Explore NIAID’s extensive resources that could facilitate your research. Resources include reagents, model organisms, clinical trial data, and more. Use our easy-to-navigate search page to filter results and locate tools that match your needs. Learn more at https://go.nih.gov/7lVbgwO #ResearchResources

In the February 26, 2025 #NIAIDFunding News, review the situations in which your application must use a modular budget and how to complete the form. Consider a new initiative for translational research on asthma and allergic diseases, as well as an opportunity to study mechanisms of combination adjuvants. Know the difference between a letter of support and a reference letter in the context of an #NIH grant application. Finally, check out our answers to reader questions about program officer assignments and small business eligibility criteria. Learn more at https://go.nih.gov/kWsiPa1

FOOD ALLERGY NEWS: Eating gradually increasing doses of store-bought, home-measured peanut butter for about 18 months in a clinical trial enabled 100% of children with #PeanutAllergy who initially could tolerate at least half a peanut to eat three tablespoons of peanut butter without an allergic reaction. This easy-to-implement treatment strategy could potentially fulfill an unmet need for about half of children with peanut allergy, who already can tolerate the equivalent of at least half a peanut. The findings come from a study sponsored and funded by #NIAID and published in the journal NEJM Evidence. Learn more: https://go.nih.gov/XbUcWqa #NIH #research #ResearchAdvance #peanut #FoodAllergy #FoodAllergies #allergic #allergy #immunotherapy #OIT #FoodAllergyTreatment Icahn School of Medicine at Mount Sinai

An experimental vaccine designed against the highly pathogenic avian influenza H5N1 (HPAI H5N1) virus circulating in U.S. cattle was fully protective in research mice, according to a new study published in Nature Communications. NIAID scientists led the animal study with colleagues from HDT Bio in Seattle who developed the replicating RNA vaccine (repRNA) platform. The findings also suggest that the HPAI H5N1 circulating in the U.S. may be able to evade immunity from older H5N1 viruses. The scientists continue to develop the repRNA vaccine platform, and evaluations in additional animal models are ongoing. Learn more: https://go.nih.gov/PMsqZSG

HIV NEWS: A NIAID study describes the successful treatment of a person with multidrug-resistant HIV using a regimen including the monoclonal antibody UB-421 (semzuvolemab) and lenacapavir-based antiretroviral therapy. Levels of HIV in the person’s blood rapidly decreased within 2 weeks of beginning the regimen and were below the detection limit after one year of treatment. Read more on the NIAID Now blog: https://go.nih.gov/7ThI157 #NIAID #HIV #AIDS #MDRHIV #mAbs #lenacapavir

In the January 15, 2025 #NIAIDFunding News, check out the top 10 reasons that grant applications have electronic submission errors. Spoiler alert: PDF attachments are largely to blame. Read about DMID’s 2026 Omnibus Broad Agency Announcement, learn about a change to NIH’s Public Access Policy, and respond to a Request for Information on the #NIH Strategic Plan for Disability Health Research. Also, don’t miss NIH’s “All About Grants Podcasts.” Plus, see our answers to reader questions about investigational new drugs and font guidelines. Learn more at https://go.nih.gov/TJ6Jamw #FundingNews #NIAID

A new NIAID study published in Nature found that highly pathogenic H5N1 avian influenza virus (HPAI H5N1) administered directly into the mouth and stomach of research monkeys caused self-limiting infection with no disease signs. By comparison, other routes of transmission resulted in mild or severe disease. The findings suggest that drinking raw milk contaminated with H5N1 virus can result in infection but may be less likely to lead to severe illness. Nevertheless, exposure by raw milk should be avoided to prevent H5N1 infection and potential further spread. Learn more: https://go.nih.gov/PnjC3BS